• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Institute of Materials Science and Nanotechnology (UNAM)
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Institute of Materials Science and Nanotechnology (UNAM)
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      An outline of contributing vaccine technologies for SARS CoV2 advancing in clinical and preclinical phase-trials

      Thumbnail
      View / Download
      1.1 Mb
      Author(s)
      Naz, Sheikh Saba
      Munir, Iqra
      Date
      2022-04-21
      Source Title
      Recent Patents on Biotechnology
      Print ISSN
      1872-2083
      Electronic ISSN
      2212-4012
      Publisher
      Bentham Science Publishers
      Volume
      16
      Issue
      2
      Pages
      122 - 143
      Language
      English
      Type
      Review
      Item Usage Stats
      15
      views
      12
      downloads
      Abstract
      Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV2) is an RNA virus involving 4 structural and 16 non-structural proteins, and exhibiting high transmission potential and fatality. The emergence of this newly encountered beta coronavirus-SARS CoV2 has brought over 2 million people to death, and more than 10 billion people got infected across the globe as yet. Consequently, the global scientific community has contributed to the synthesis and design of effective immunization technologies to combat this virus. Objectives: This literature review was intended to gather an update on published reports of the vaccines advancing in the clinical trial phases or preclinical trials, to summarize the foundations and implications of contributing vaccine candidates inferring their impact in the pandemic repression. In addition, this literature review distinctly facilitates an outline of the overall vaccine effectiveness at current doses. Methods: The reported data in this review was extracted from research articles, review articles and patents published from January 2020 to July 2021, available on Google Scholar, Pubmed, Pubmed Central, Research Gate, Science direct, and Free Patent Online Database by using combination of keywords. Moreover, some information is retrieved from native web pages of vaccine manufacturing companies' due to progressing research and unavailability of published research papers. Conclusion: Contributing vaccine technologies include: RNA (Ribonucleic acid) vaccines, DNA (Deoxyribonucleic acid) vaccines, viral vector vaccines, protein-based vaccines, inactivated vaccines, viruses-like particles, protein superglue, and live-attenuated vaccines. Some vaccines are prepared by establishing bacterial and yeast cell lines and as self-assembling adenovirus- derived multimeric protein-based self-assembling nanoparticle (ADDOmer). On May 19, WHO has issued an emergency use sanction of Moderna, Pfizer, Sinopharm, AstraZeneca, and Covishield vaccine candidates on account of clinical credibility from experimental data.
      Keywords
      DNA vaccines
      Immunization technologies
      RNA vaccines
      SARSCoV-2 infection
      SARSCoV-2 vaccines
      Permalink
      http://hdl.handle.net/11693/111990
      Published Version (Please cite this version)
      https://www.doi.org/10.2174/1872208316666220118094344
      Collections
      • Institute of Materials Science and Nanotechnology (UNAM) 2258
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCoursesThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCourses

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 2976
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy